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the treatment of chronic myeloid leukemia (CML). However, although extremely effective in inducing CML re-
mission, IM is unable to eliminate leukemia stemcells (LSC). This is largely due to the suppression of BCR/Abl pro-
tein, driven by the reduction of energy supply due to oxygen or glucose shortage, in stem cell niches of bone
marrow. Here, we investigated whether, in K562 and KCL22 CML cell cultures, glucose shortage induces refrac-
toriness of stem cell potential to IM. In the absence of glucose, IM, while maintaining its detrimental effect on
CML cell bulk, actually enhanced colony formation ability and stem cell potential. This was paralleled by an in-
creased expression of the Nanog and Sox-2 stem cell markers. These evidences stress further the importance of
developing strategies alternative to TKI capable to target LSC of CML.
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Chronic myeloid leukemia (CML) is a hematopoietic disease driven
by the t9;22 translocation, which results in the expression of the “fu-
sion” protein BCR/Abl, a constitutively active tyrosine kinase
(Holyoake and Vetrie, 2017; Gambacorti-Passerini et al., 2016). Ima-
tinib-mesylate (IM), the prototype of tyrosine kinase inhibitors (TKI)
capable to target the enzymatic activity of BCR/Abl oncoprotein, is ex-
tremely efficient in ensuring deep molecular response and prolonged
survival in chronic-phase CML patients (Druker et al., 2001). However,
a critical aspect of the outcome of TKI treatment is that, in most of
even well-responding patients, disease relapses when TKI treatment is
interrupted (Mahon et al., 2010). This is most likely due to the fact
that leukemia stem cells (LSC), the CML cell subset believed to sustain
minimal residual disease (MRD) and the consequent risk of recurrence
(Ghiaur et al., 2012), are insensitive to TKI (Graham et al., 2002;
Corbin et al., 2011).
We previously found that incubation of CML cells in atmosphere at
very low oxygen tension time-dependently determines BCR/Abl proteine Biomediche Sperimentali e
0134, Italy.
tteo.lulli@unifi.it (M. Lulli).
. This is an open access article undersuppression, so that LSC that are maintained under these conditions are
refractory to TKI due to the lack of the TKI molecular target (Giuntoli et
al., 2006; Cheloni et al., 2017a; Cheloni et al., 2017b). The point is rele-
vant in view of the fact that normal hematopoietic stempotential is pre-
served in stem cell niches placed in bone marrow (BM) areas where
oxygen tension is physiologically very low (Parmar et al., 2007). We
envisioned on these bases a model in which MRD of CML persists due
the capacity of LSC to survive under serious energy constraints indepen-
dently of BCR/Abl signaling (Rovida et al., 2014). These LSC, however,
remain leukemic at the BCR/abl transcript level, so that they are capable,
when transferred to conditions where BCR/Abl protein can be
expressed, to undergo BCR/Abl-dependent clonal expansion and
thereby determine relapse of disease (Giuntoli et al., 2006; Giuntoli et
al., 2011).
The shortage of glucose, like that of oxygen, represents a crucial path
to energy restriction, due to the importance of glucose oxidation in cell
metabolism. We recently showed that glucose shortage also leads to
BCR/Abl protein suppression (Bono et al., 2016). On this basis, we de-
cided to determine whether glucose shortage induces refractoriness of
CML stem cell potential to IM. We found that, in K562 and KCL22 CML
cell cultures established in the absence of glucose, IM maintains its ac-
tivity and consequently reduces the total number of viable cells. How-
ever, in IM-treated cultures, the maintenance of stem cell potential
was markedly enhanced. Accordingly, the expression of the Nanogthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consequences of these facts are discussed.
2. Materials and methods
2.1. Cells and culture conditions
K562 blast-crisis CML cells (Lozzio and Lozzio, 1975) were pur-
chased from theGermanCollection of Cell Cultures (Braunschweig, Ger-
many) and routinely cultured in RPMI 1640 medium supplemented
with 2 g/L D-glucose, 10% heat-inactivated foetal bovine serum, 2 mM
L-glutamine, 50 units/mL penicillin and 50 μg/mL streptomycin (all
from EuroClone, Paington, UK). Most experiments were carried out
using RPMI 1640 medium without D-glucose (Gibco by ThermoFisher
Scientific, Waltham, MA, USA) supplemented as above. IM was dis-
solved in PBS (EuroClone) and IM-untreated cultures were also PBS-
supplemented. Experiments were performed with cells harvested
from exponentially-growing routine cultures and subcultured (5
× 105/mL) in freshmedium24h before plating (3× 105/mL). Incubation
was carried out at 37 °C in water-saturated atmosphere containing 5%
CO2 and 21% O2. Viable cells were counted in a hemocytometer by
trypan blue exclusion.
2.2. Colony Formation Ability (CFA) assay
Cells rescued from cultures established as described above in the ab-
sence of glucose and treated or not with IM (Liquid Culture 1 - LC1)
were washed free of drug and replated (3 × 103/35-mm dish) at differ-
ent times of incubation into IM-free, methylcellulose-containing sec-
ondary semisolid cultures (#04432, Stem Cell Technology, Vancouver,
BC, Canada) supplemented with standard glucose concentration. Colo-
nies were counted after 10 days.
2.3. Culture Repopulation Ability (CRA) assay
The CRA assay is an in vitro substitute for the marrow repopulation
ability assay in vivowhere the estimate of stem cell potential is obtained,
rather than transplanting cells into animals, via cell transfer to liquid
cultures (LC2) (Cheloni and Tanturli, 2016; Cipolleschi et al., 2000,
2013; Giuntoli et al., 2006, 2011; Ivanovic et al., 2000; Ivanovic et al.,
2002).
Cells from LC1 established as described above were washed free of
drug and replated (3 × 104 cells/mL), at different times of incubation
in LC1, into IM-free secondary LC2 containing standard glucose concen-
tration. Culture medium was never changed during LC1 or LC2. The ki-
netics of viable cell number in LC2 provides an estimate of the CRA of
LC1 cells.
2.4. Cell protein content analysis
Cells were washed once with ice-cold phosphate buffered saline
(PBS) containing 100 μM Na3VO4. Total cell lysates were obtained in
Laemmli buffer (62.5 mM Tris/HCl, pH 6.8, 10% glycerol, 0.005%
bromophenol blue, and 2% SDS), while hypotonic buffer (10 mM
HEPES, 10 mM NaCl, 5 mM NaHCO3, 1 mM CaCl2-2H2O, 0.5 mM
MgCl2-6H2O, 5 mM Na2EDTA, 20 mM Na4P2O7, 10 mM NaF, supple-
mented with protease inhibitors: 100 μM Na3VO4, 1 mM PMSF,
0.1 U/mL Aprotinin, 4 μg/mL Pepstatin, 10 μg/mL TPCK, all from
Sigma-Aldrich, St. Louis, MO, USA) was used for cytosol/nucleus separa-
tion. Protein concentration was determined by the BCA method
(#23225, Pierce™ BCA Protein Assay Kit by Thermo Fisher Scientific)
and 50–80 μg protein/sample were subjected to SDS-PAGE. Separated
proteins were transferred onto nitrocellulose membranes
(#10600002, Amersham™ Protran™ 0.45 μm NC by GE Healthcare
Life Sciences, Little Chalfont, Buckinghamshire, UK) by electroblotting.Membranes were blocked in a 1:1 dilution of Odyssey (LI-COR® Biosci-
ences, Lincoln, NE, USA) blocking buffer (OBB) with PBS for 1 h at room
temperature (RT) and then incubated (overnight, 4 °C) with primary
antibody in a 1:1 dilution of OBBwith PBS-0,1% Tween (T-PBS). Primary
antibodies used were: anti-c-Abl (K-12), rabbit polyclonal (#sc-131),
anti-Sox-2 (E-4), mouse monoclonal (#sc-365823), anti-Fibrillarin (D-
14), goat polyclonal (#sc-11336) (all from Santa Cruz Biotechnology,
Santa Cruz, CA, USA); anti-Nanog (D73G4) XP, rabbit monoclonal
(#4903, Cell Signaling Technology, Danvers, MA, USA), anti-Vinculin
(clone hVIN-1), mouse monoclonal (#V9131, Sigma-Aldrich). Washed
membranes were incubated for 1 h at RT in 1:1 OBB/T-PBS containing
an IRDye®800CW- or IRDye®680-conjugated secondary antibody
(Lulli et al., 2012). Antibody-coated protein bands were visualized and
quantified by the Odyssey Infrared Imaging System (LI-COR® Biosci-
ences), as previous reported (Witort et al., 2013).2.5. Statistical analysis
Data are presented as the mean ± SD (unless indicated otherwise)
of independent experiments and were compared by using a Student's
t-test. P values (p) of b0.05 were considered statistically significant.3. Results
3.1. IM affects K562 and KCL22 cell survival and growth under glucose
shortage
The effects of IM on K562 cell growth under our standard incubation
conditions are shown in Fig. 1A. Viable cell number underwent a 5-fold
increase, peaking on day 10, to decline thereafter as an effect of culture
exhaustion. IM addition on day 3 determined a minor, although signifi-
cant, effect until day 5, to induce thereafter a marked decrease of cell
number, as expected. The effects of IM addition on day 2, 4 or 7 were
then evaluated under glucose shortage (Fig. 1B), a condition where
CML cell growth is reduced (Bono et al., 2016). IM treatment reduced
cell number, the effect being the more marked, the earlier the IM ad-
ministration. Such an outcome is in keeping with the progressive sup-
pression, under our experimental conditions, of BCR/Abl protein, the
molecular target of IM. Indeed, we previously demonstrated in K562
cells a reduction of about 25, 70 or 100% of BCR/Abl protein expression
after 2, 4 or 7 days, respectively, of glucose shortage (Bono et al., 2016).
Thus, IM activity was maintained under glucose shortage, although the
effect of the drugwas progressively quenched during culture decline, so
that IMadministered on day 7 of incubationwas ineffective at least until
day 14. A similar resultwas obtained in KCL22 cells, the growth ofwhich
under glucose shortage was markedly reduced by IM addition on day 2
(Bono et al., 2018).3.2. IM enhances Colony Formation Ability of K562 cells under glucose
shortage
IM treatment was also tested by CFA assay (Fig. 2). K562 cells res-
cued from glucose-free liquid cultures treated or not with IM from dif-
ferent times of incubation were transferred on day 10 or day 14 to
non-selective (standard glucose concentration, no IM) secondary semi-
solid cultures. In either case, IM enhanced CFA, the effect being themore
marked, the earlier the IM treatment. Like in the experiments of Fig. 1B,
the effect of IMwas zeroedwhen treatment was applied after cell num-
ber in culture started to decline (day 7). The yield of cells transferred to
semisolid cultures on day 14 (Fig. 2B) was lower than that of cells trans-
ferred on day 10 (Fig. 2A), most likely as result of the progressive disap-
pearance of clonogenic progenitors in liquid cultures.
Fig. 1. Effects of IM on K562 cell survival and growth in the presence or the absence of glucose. K562 cells were plated at 3 × 105 cells/mL and incubated under standard conditions in the
presence (A) or the absence (B) of glucose: (o) untreated control; (●) IM administered on day 3 (A) or day 2 (B); (▲) IM on day 4; (■) IM on day 7. Viable cells were counted by trypan
blue exclusion at the indicated times. Data represent themean± SD of 10 independent experiments. A: **p b 0.01 (●) vs (o) from day 7, *p b 0.05 (●) vs (o) day 5. B: **p b 0.01 (●) vs (o)
from day 6, *p b 0.05 (●) vs (o) day 4; **p b 0.01 (▲) vs (o) from day 7 to day 9, *p b 0.05 (▲) vs (o) from day 10 (two-tailed Student's t-test).
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der glucose shortage
The effects of glucose shortage and IM treatment on the mainte-
nance of CML stem cell potential in culture were then tested by CRA
assay (Fig. 3 and Bono et al., 2018). K562 cells from cultures established
in the absence of glucose and treatedwith IM on different times of incu-
bation (LC1) like in Fig. 1B, were transferred on day 10 (Fig. 3A) or 14
(Fig. 3B) to non-selective (standard glucose concentration, no IM) sec-
ondary LC2. With IM-treated LC1 cells, the increase of viable cell num-
ber in LC2 was the more rapid and marked, the earlier the IM
treatment of LC1. Here again, the effect of IM was zeroed when treat-
ment was applied during the decline phase of LC1. This effect was mag-
nified in the experiments of Fig. 3B, where day-14 LC1 cells were
transferred to LC2. In IM-untreated cells rescued from day-14 LC1, un-
like in those from day-10, stem cell potential was undetectable. A simi-
lar result was obtained with KCL22 cells, where IM treatment on day 2
of LC1 determined a marked increase of viable cell number in LC2 com-
pared to IM-untreated cells (Bono et al., 2018). Therefore, IM treatment
during the florid phase of LC1 (day 2 or 4 for K562 cells, day 2 for KCL22
cells) determined a massive LC2 repopulation, indicating that IM
protected stem cell potential from its suppression in glucose-free
cultures.Fig. 2. Effects of IM on CFA assay of glucose-free K562 cell cultures. K562 cells were cultured (3
times to day 10 (A) or 14 (B) of incubation. Cells were then washed free of drug and replat
supplemented with standard glucose concentration. Colonies were counted after 10 days.
control (two-tailed Student's t-test).3.4. Nanog and Sox-2 protein expression is increased by IM inK562 cells un-
der to glucose shortage
The impact of IMon themaintenance of stemcell phenotype of K562
cells under glucose shortage was evaluated not only at the functional,
but also at the molecular level. Fig. 4A (upper blot) shows, first of all,
that BCR/Abl protein is suppressed in the absence of glucose, an event
we extensively described and characterized (Bono et al., 2016). In the
same experiments, the effects of IM on the expression of stem cell
markers were also addressed. IM enhanced Nanog expression (Fig.
4A), the effect being visible when treatment was applied on day 2 or
day 4, but not day 7, with either day-10 or day-14 cells. Sox-2 expres-
sion was evaluated following cytosol/nucleus separation (Fig. 4B). IM
markedly enhanced nuclear Sox-2 expression, again with similar out-
come for day-10 (left) and day-14 cells (right). These data well explain
the effects of IM on stem cell potential shown in Fig. 3.4. Discussion
We had previously demonstrated that, under energy restriction,
BCR/Abl protein is time-dependently suppressed (Bono et al., 2016),
while a CML cell subset endowed with progenitor/stem cell properties
is maintained (Giuntoli et al., 2006, 2011). The study reported here
showed that a similar cell subset was maintained when energy restric-
tionwas driven via glucose shortage, and addressed the effects of IM ap-
plied when (days 2 or 4 for K562, day 2 for KCL22) cells still express× 105/mL) in glucose-free liquid medium and treated or not with IM from the indicated
ed (3 × 103/35-mm dish) into IM-free, methylcellulose-containing semisolid medium
Data represent the mean + SD of 4 independent experiments. **p b 0.01 vs untreated
Fig. 3. Effects of IM on stem cell potential (CRA assay) of glucose-free K562 cell cultures. K562 cells were cultured (3 × 105/mL) in glucose-free liquid cultures (LC1) and treated or not (o)
with IM fromday 2 (●), day 4 (▲) or day 7 (■). Onday 10 (A) or 14 (B) of incubation in LC1, cellswerewashed free of drug and replated (3× 104/mL) into IM-free LC2 supplementedwith
standard glucose concentration. The maintenance of stem cell potential at the end of LC1 was determined by counting viable cells (trypan blue exclusion) at the indicated times of
incubation in LC2. Data represent the mean ± SD of 7 independent experiments. A: **p b 0.01 (●) vs (o) from day 11 to day 23, *p b 0.05 (●) vs (o) from day 25 to day 32; **p b 0.01
(▲) vs (o) from day 14 to day 21, *p b 0.05 (▲) vs (o) from day 23 to day 28. B: **p b 0.01 (●) vs (o) from day 11; **p b 0.01 (▲) vs (o) from day 18 (two-tailed Student's t-test).
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cell bulk reacts differently from progenitor/stem cells to energy restric-
tion and that glucose shortage is adequate to highlight their different re-
sponse to IM is witnessed by the opposite effects determined by day-2
or day-4 IM treatment in Fig. 1B when compared to Figs. 2 and 3.
While IM decreased cell bulk, as expected, it increased the yield of pro-
genitor/stem cell assays. This is a remarkable finding, as in a previous
study where energy restriction was driven via incubation of K562 cells
in low-oxygen atmosphere (Giuntoli et al., 2011), stem cell potential
was proved to be refractory to IM, but by no means enhanced by IM
like in the experiments of Fig. 3. This indicates that, while stem cell po-
tential maintained under energy restriction is generally insensitive to
IM, different types ofmetabolic pressure impact differently the response
to IM.
CFA was also markedly enhanced in the presence of IM (Fig. 2), a
finding that matches closely that obtained for stem cell potential asFig. 4. Effects of IM on the expression of BCR/Abl and stem cell markers in glucose-free K562 ce
not with IM from the indicated times and lysed on day 10 or 14 of incubation. Total cell lysate
blotting with the indicated antibodies. Vinculin (cytosolic) and fibrillarin (nuclear) were useddetermined by CRA assay (Fig. 3 and Bono et al., 2018). These results
do not contradict the notion that CML non-stem progenitors capable
to form colony in semisolid medium are sensitive to IM (Belle et al.,
2012). In our experiments, indeed, CFA assays were not established
with cells directly recovered from routine cultures, but following a 10
or 14 day-long selective incubation in liquid medium under glucose
shortage. This implies that clonal expansion in semisolid medium was
measured after a 20- to 24-day total transit time from the beginning
of IM treatment. This time is closer to that of CRA assay (30 to 34 days
to peak of LC2), which provides an estimate of stem cell potential,
than to that of standard CFA assay (colonies scored on day 10). Thus,
in our study, CFA assays reflect clonogenic progenitors of significantly
higher hierarchical level than that of standard in vitro colony-forming
cells. We believe that this conclusion is appropriate to explain the sim-
ilar outcome of the experiments of Figs. 2 and 3.ll cultures. K562 cells were cultured (3 × 105/mL) in glucose-free liquid cultures treated or
s (A) or lysates subjected to cytosol/nucleus separation (B) were processed for immuno-
as loading control.
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rescued fromday-10 (A) or day-14 (B) LC1 provides additional informa-
tion. The two different incubation times led to different combinations of
stem/progenitor cells, as indicated by the fact that, from day 10 to day
14 of incubation under glucose shortage, CFA declined (Fig. 2), while
CRA increased (Fig. 3). This is most probably the result of the progres-
sive concentration in culture of stem/progenitor cells of higher hierar-
chical level. Irrespective of those differences, IM enhanced the yield of
either assay, provided it was administered before BCR/Abl suppression
(day 2 or 4). Fig. 3 requires a further comment. The differences between
experimental variants were magnified in B, where, with respect to A,
the curves of LC2 repopulation were much more scattered and, more
importantly, the stem cell potential in the absence of IM (or with IM ad-
dition on day 7) was completely suppressed instead of reduced. Thus,
the longer stem cell selection in culture, the higher the detrimental ef-
fects of glucose shortage (control cultures) aswell as the stimulatory ef-
fects of IM.
LC2 repopulation reflects the growth-promoting effect of BCR/Abl
re-expression following the transfer of LC1 cells into the growth-per-
missive LC2 environment (Giuntoli et al., 2006, 2011).When conditions
suppressing BCR/Abl signaling (for instance, IM treatment or oxygen
and/or glucose shortage) are established, CML cells capable to survive
in its absence are primed to rescue BCR/Abl protein expression, once
conditions permissive for clonal expansion are restored, more rapidly
than at the steady-state turnover (Giuntoli et al., 2006; Weisberg and
Griffin, 2000). However, the differences between the results shown in
A and B of Fig. 3 seem related, rather than to a question of enhanced
BCR/Abl protein re-expression, to a better maintenance of stem cell po-
tential. A strong indication in this direction is provided by the data rel-
ative to the expression of Nanog and Sox-2 proteins, stem cell markers
in different hematological malignancies (Gelebart et al., 2012;
Kakiuchi et al., 2017; Xin et al., 2013), which was enhanced in the pres-
ence of IM, again only when the IM target BCR/Abl was expressed (Fig.
4).
That the block of BCR/Abl signaling by IM enhanced themaintenance
of stem cell potential under glucose shortage is the main result of our
study. This is especially evident in Fig. 3B, where stem cell potential
was completely suppressed under control conditions. Our hypothesis
to explain the finding that IM protected stem cell compartment under
energy restrictions is as follows. We previously demonstrated that
sustained IL3-induced proliferation of normal BMC steers the cycling
of metabolically-selected stem cells to boost clonal expansion, while
constraints on those stimuli privilege self-renewal (Ivanovic et al.,
2002). In CML, the maintenance of the IL3-mimetic BCR/Abl signaling
(Jiang et al., 2002) is apparently detrimental to stem cell adaptation to
energy restriction (Rovida et al., 2014), so that stem cell potential is bet-
ter capable to stand glucose shortage when excessive BCR/Abl-depen-
dent growth stimulation is quenched by IM. It is to underscore again
here that this can be obtained only if the CML stem cell subset involved
in the phenomenon (I) expresses themolecular target of IM (day 2 or 4
of incubation) and (II) is capable to survive when BCR/Abl signaling is
suppressed or strongly reduced (day 7 and beyond). CML cell bulk, on
the contrary, decreases under IM treatment because addicted to full
BCR/Abl-dependent growth stimulation (Cheloni et al., 2017a). The
relationship between hematopoietic growth factors, glucose supply
and cell survival is long-known (Dexter et al., 1984; Whetton et al.,
1984).
The physiological occurrence of low-glucose areas in hematopoietic
tissue in vivo is under question. Areas where glucose gets close to ex-
haustion have been shown in solid tumors (Tannock, 1968) and are
very likely to characterize the hyperplastic BM of CML patients. Glucose
shortage also appears compatible with normal BM, where areas at very
low blood perfusion host the most primitive HSC (Winkler et al., 2010).
In any case, we consider the findings reported here as a proof of concept
that the treatment with IM or other TKI, while remarkably effective in
CML debulking and induction of remission, may be detrimental to afavorable long-term outcome of disease, not because just inactive on
the LSC compartment (Giuntoli et al., 2006, 2011; Cheloni et al.,
2017a), but because actually capable to protect its maintenance.
Finally, it is necessary to comment here on the fact that permanent
suppression of MRD following TKI treatment seems to be achieved in
a small fraction of patients. Our hypothesis to explain such a favorable
outcome lies in the dual CML stem cell model we proposed, where a
BCR/Abl-independent LSC subset resistant to energy restriction and
dedicated to MRD maintenance is dynamically related to another,
downstream BCR/Abl-dependent LSC subset committed to clonal ex-
pansion (Rovida et al., 2014). In some patients, TKI-induced stress on
the latter subset might be temporarily compensated by the former,
until LSC capable to sustain MRD themselves are exhausted.
5. Conclusions
We show here that under glucose shortage IM treatment results in
an enhancement of CML stem cell potential. This represents a proof of
concept that the treatment with IM or other TKI may be detrimental
to a favorable long-term outcome of CML due to adverse effects of ther-
apy related to an enhanced persistence of MRD.
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